Gabather AB (publ) (STO:GABA)

Market Cap	20.15M +90.4%
Revenue (ttm)	n/a
Net Income	-5.38M
EPS	-0.02
Shares Out	610.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0330
Previous Close	0.0330
Day's Range	0.0330 - 0.0330
52-Week Range	0.0230 - 0.1300
Beta	-0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GABA

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 17, 2026

Data Sources Report a data error